<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809988</url>
  </required_header>
  <id_info>
    <org_study_id>MedOPP068</org_study_id>
    <secondary_id>2017-002781-48</secondary_id>
    <nct_id>NCT03809988</nct_id>
  </id_info>
  <brief_title>PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)</brief_title>
  <acronym>PALMIRA</acronym>
  <official_title>International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedSIR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedSIR</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative&#xD;
      advanced breast cancer (ABC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre- and post-menopausal women age ≥ 18 years with HR-positive and HER2-negative with ABC&#xD;
      that had previously received first-line endocrine therapy in combination with palbociclib and&#xD;
      had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a&#xD;
      palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not&#xD;
      eligible if they are candidates for a local treatment with a curative intention. Evidence of&#xD;
      either measurable and biopsiable metastatic disease (as for Response Evaluation Criteria In&#xD;
      Solid Tumors (RECIST v.1.1)) or non-measurable disease with bone lesion is required.&#xD;
      Pre-menopausal women must be under treatment with luteinizing hormone-releasing hormone&#xD;
      (LHRH) analogues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (Progression-free survival)</measure>
    <time_frame>Baseline up to 29 months</time_frame>
    <description>From a clinical point of view, the primary endpoint for this study is the PFS (progression-free survival) - defined as the period of time from randomization until objective tumor progression or death - assessed by RECIST criteria v.1.1, of continuation of palbociclib treatment combined with second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy in pre- and post- menopausal women with HR-positive/HER2-negative ABC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety AEs</measure>
    <time_frame>Baseline up to 29 months</time_frame>
    <description>Patient safety and adverse events (AEs) will be evaluated using the NCI-CTCAE v.5.0. Grade 3 and 4 AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the different treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (ORR)</measure>
    <time_frame>Baseline up to 29 months</time_frame>
    <description>To compare the objective response rate (ORR), the duration of response (DoR), the time to response (TTR), the clinical benefit rate (CBR), the time to progression (TTP), and the overall survival (OS) of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Quality of Life)</measure>
    <time_frame>Baseline up to 42 months</time_frame>
    <description>To compare the patient reported global Quality of Life (QOL), functioning and symptoms of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of subgroup analysis</measure>
    <time_frame>Baseline up to 42 months</time_frame>
    <description>To perform subgroup analysis for primary and secondary endpoints in stratified groups of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare efficacy</measure>
    <time_frame>Baseline up to 42 months</time_frame>
    <description>To compare the time to first chemotherapy of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory objectives (molecular markers)</measure>
    <time_frame>Baseline up to 42 months</time_frame>
    <description>To explore potential molecular markers of sensitivity and/or resistance for the combination and endocrine therapy alone, according to, but not limited to, the results obtained from the BioPER trial (NCT03184090).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory objectives (intrinsic molecular subtypes)</measure>
    <time_frame>Baseline up to 42 months</time_frame>
    <description>To explore correlations between the intrinsic molecular subtypes and efficacy/safety findings in patients with HR-positive/HER2- negative ABC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>Interventional Arm (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive endocrine therapy (letrozole or fulvestrant).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks</description>
    <arm_group_label>Interventional Arm (Arm A)</arm_group_label>
    <other_name>IBRANCE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Endocrine therapy alone (letrozole or fulvestrant)</description>
    <arm_group_label>Control Arm (Arm B)</arm_group_label>
    <arm_group_label>Interventional Arm (Arm A)</arm_group_label>
    <other_name>letrozole</other_name>
    <other_name>fulvestrant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients over 18 years of age.&#xD;
&#xD;
          2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least&#xD;
             28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating&#xD;
             hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal&#xD;
             women as defined by any of the following criteria:&#xD;
&#xD;
               1. Age ≥60 years;&#xD;
&#xD;
               2. Age &lt;60 years and cessation of regular menses for at least 12 consecutive months&#xD;
                  with no alternative pathological or physiological cause; and serum estradiol&#xD;
                  and/or FSH level within the laboratory's reference range for postmenopausal&#xD;
                  females;&#xD;
&#xD;
               3. Documented bilateral oophorectomy.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1.&#xD;
&#xD;
          4. Life expectancy greater or equal to 12 weeks.&#xD;
&#xD;
          5. Histologically proven diagnosed of ABC not amenable to curative treatment.&#xD;
&#xD;
          6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with ≥1%&#xD;
             positive stained cells (according to NCCN National Comprehensive Cancer Network and&#xD;
             ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by&#xD;
             immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test)&#xD;
             breast cancer in the advanced setting.&#xD;
&#xD;
          7. Radiological or clinical evidence of disease progression on first- line combination of&#xD;
             palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients&#xD;
             previously treated with the combination of palbociclib and tamoxifen will be excluded.&#xD;
&#xD;
          8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based&#xD;
             endocrine regimen (defined as at least stable disease ≥ 24 weeks or partial or&#xD;
             complete response confirmed or unconfirmed).&#xD;
&#xD;
          9. Patients must have been treated with a stable minimum dose of 100 mg palbociclib&#xD;
             during the last 2 cycles of the prior palbociclib-based regimen.&#xD;
&#xD;
         10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7&#xD;
             days from study entry, with the exception of patients relapsing on a palbociclib-based&#xD;
             regimen in the adjuvant setting.&#xD;
&#xD;
         11. Patients should not have been treated in the advanced setting with at least one of&#xD;
             these endocrine therapy options: either fulvestrant or AI.&#xD;
&#xD;
         12. Patients must have measurable disease or evaluable disease according to RECIST&#xD;
             criteria v.1.1. Patients with only bone lesions are eligible.&#xD;
&#xD;
         13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the&#xD;
             inclusion and after disease progression in order to perform exploratory studies. If&#xD;
             not feasible, patient eligibility should be evaluated by a Sponsor's qualified&#xD;
             designee.&#xD;
&#xD;
         14. Patients agree to collection of blood samples (liquid biopsy) at the time of&#xD;
             inclusion, after 2 weeks of treatment, and upon progression or study termination.&#xD;
&#xD;
         15. Adequate organ function: (Hematological, hepatic and renal)&#xD;
&#xD;
         16. Patients who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
         17. Patients have been informed about the nature of study, and have agreed to participate&#xD;
             in the study, and signed the informed consent form prior to participation in any&#xD;
             study-related activities.&#xD;
&#xD;
         18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HR or HER2 unknown disease.&#xD;
&#xD;
          2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test).&#xD;
&#xD;
          3. Locally ABC candidate for curative treatment.&#xD;
&#xD;
          4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or&#xD;
             symptomatic progressive visceral disease.&#xD;
&#xD;
          5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib.&#xD;
&#xD;
          6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases,&#xD;
             carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,&#xD;
             cerebral edema, and/or progressive growth. Patients with a history of CNS metastases&#xD;
             or cord compression are eligible if they have been definitively treated and are&#xD;
             clinically stable off anticonvulsants and steroids for at least 4 weeks before&#xD;
             randomization.&#xD;
&#xD;
          7. Patients are currently receiving food or drugs known to be strong inducers or&#xD;
             inhibitors of CYP3A4.&#xD;
&#xD;
          8. Current or prior malignancy which could affect compliance with the protocol or&#xD;
             interpretation of results. Patients with curatively- treated non-melanoma skin cancer,&#xD;
             non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally&#xD;
             eligible.&#xD;
&#xD;
          9. No other systemic therapy for metastatic disease including chemotherapy,&#xD;
             immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine&#xD;
             therapy excluding first-line palbociclib-based regimen.&#xD;
&#xD;
         10. Major surgery (defined as requiring general anesthesia) or significant traumatic&#xD;
             injury within 2 weeks of start of study drug, or patients who have not recovered from&#xD;
             the side effects of any major surgery, or patients who may require major surgery&#xD;
             during the study.&#xD;
&#xD;
         11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study&#xD;
             enrolment, or patients who have not recovered from radiotherapy-related toxicities to&#xD;
             baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously&#xD;
             irradiated.&#xD;
&#xD;
         12. Use of concurrent investigational agents or other concomitant anticancer therapies.&#xD;
&#xD;
         13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic&#xD;
             anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon&#xD;
             as it is used as prophylaxis intention).&#xD;
&#xD;
         14. Serious concomitant systemic disorder (e.g., active infection including HIV, or&#xD;
             cardiac disease) incompatible with the study (at the discretion of investigator).&#xD;
&#xD;
         15. Unable to swallow capsules or tablets.&#xD;
&#xD;
         16. History of malabsorption syndrome or other condition that would interfere with enteral&#xD;
             absorption.&#xD;
&#xD;
         17. Any of the following within 6 months of randomization:&#xD;
&#xD;
             myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of&#xD;
             NCI-CTCAE v.5.0 grade ≥2, coronary/peripheral artery bypass graft, symptomatic&#xD;
             congestive heart failure, cerebrovascular accident including transient ischemic&#xD;
             attack, or symptomatic pulmonary embolism.&#xD;
&#xD;
         18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ≥ 2.&#xD;
&#xD;
         19. Known hypersensitivity to palbociclib or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Perez</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedSIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Zafra</last_name>
    <phone>+34 687 246 755</phone>
    <email>mariadelmar.zafra@medsir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia García</last_name>
    <phone>+34 611 261 467</phone>
    <email>alicia.garcia@medsir.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dobi Erion</last_name>
    </contact>
    <investigator>
      <last_name>Dobi Erion</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Hennequin</last_name>
      <email>ahennequin@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Audrey Hennequin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Priou, MD</last_name>
      <email>frank.priou@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Medioni, MD</last_name>
      <email>jacques.medioni@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Gligorov, MD</last_name>
      <email>joseph.gligorov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Petit, MD</last_name>
      <email>tpetit@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden-GYN</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, MD</last_name>
      <email>Pauline.wimberger@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattea Reinisch, MD</last_name>
      <email>M.Reinisch@kliniken-essen-mitte.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Frauenklinik</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Rainer Kimming, MD</last_name>
      <email>rainer.kimmig@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGAPLESION Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Thill, MD</last_name>
      <email>Marc.Thill@fdk.info</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Ettl, MD</last_name>
      <email>johannes.ettl@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKM Brustzentrum</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Tio, MD</last_name>
      <email>joke.tio@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea Fischer, MD</last_name>
      <email>Dorothea.Fischer@klinikumevb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen Trier</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, MD</last_name>
      <email>mahlberg@mutterhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civili Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Vassalli, MD</last_name>
      <email>lucia.vassalli@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Colleoni, MD</last_name>
      <email>marco.colleoni@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Ospedale di Prato</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Biganzoli, MD</last_name>
      <email>laura.biganzoli@uslcentro.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Santini, MD</last_name>
      <email>d.santini@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanesa Quiroga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castello</city>
        <state>Castelló</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Martínez de Dueñas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Terrasa</state>
        <zip>08191</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ramos Vázquez</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Ramos Vázquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Fernández</last_name>
    </contact>
    <investigator>
      <last_name>Adela Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Bellet, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Meritxell Bellet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sonia Servitja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purificación Martínez</last_name>
    </contact>
    <investigator>
      <last_name>Purificación Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago González</last_name>
    </contact>
    <investigator>
      <last_name>Santiago González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Del Barco</last_name>
    </contact>
    <investigator>
      <last_name>Sonia Del Barco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serafin Morales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Garcia-Saenz</last_name>
    </contact>
    <investigator>
      <last_name>Jose Angel Garcia-Saenz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Vega</last_name>
    </contact>
    <investigator>
      <last_name>Estela Vega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Zamora</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Diaz Redondo</last_name>
    </contact>
    <investigator>
      <last_name>Tamara Diaz Redondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Perello Martorell</last_name>
    </contact>
    <investigator>
      <last_name>Antonia Perello Martorell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kepa Amillano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis de la Cruz Merino</last_name>
    </contact>
    <investigator>
      <last_name>Luis de la Cruz Merino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ruiz Borrego</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología IVO</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kino Gávila</last_name>
    </contact>
    <investigator>
      <last_name>Kino Gávila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª José Godes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Carañana, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Santaballa, MD</last_name>
      <email>santaballa_ana@gva.es</email>
    </contact>
    <investigator>
      <last_name>Ana Santaballa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaura Fernandez Perez</last_name>
    </contact>
    <investigator>
      <last_name>Isaura Fernandez Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Andres, Phd</last_name>
      <phone>+34 976 76 57 69</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Antón</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Antón</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iain MacPherson</last_name>
      <email>Iain.MacPherson@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Iain MacPherson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Cancer Institute</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schmid</last_name>
      <email>p.schmid@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Peter Schmid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kent Oncology Department</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Harper-Wynne</last_name>
      <email>charperwynne@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Catherine Harper-Wynne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA127BR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Davis, MD</last_name>
      <email>mark.davies44@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital NHS Trust</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Wheatley</last_name>
      <email>duncanwheatley@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Duncan Wheatley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR</keyword>
  <keyword>breast cancer</keyword>
  <keyword>ABC</keyword>
  <keyword>progesterone receptor</keyword>
  <keyword>HER2</keyword>
  <keyword>advanced</keyword>
  <keyword>estrogen receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Leaflet V2_20190115 with study design, primary objetive, inclusion criteria and exclusion criteria</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>During recruitment period</ipd_time_frame>
    <ipd_access_criteria>Oncology department</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

